Navigation Links
Alzheimer's Treatment Trials May Have Special Challenges
Date:7/28/2008

Studies may need larger pools of participants to accurately assess if drugs are effective

MONDAY, July 28 (HealthDay News) -- It may be harder to prove the effectiveness of new Alzheimer's disease therapies, because researchers have been having a hard time finding measurable decline in memory and thinking processes in the placebo groups the drugs are being tested against, according to two new reports.

Several discoveries may explain this, according to the reports, which are expected to be presented Monday in Chicago at the Alzheimer's Association's International Conference on Alzheimer's Disease.

In the first study, researchers looked at 87 randomized, double-blind, placebo-controlled Alzheimer clinical trials conducted between 1991 and 2005. Their analysis help set conditions that may be optimal in these types of trials.

"Based on our analysis, the most reliable approach to maximize the likelihood for demonstrating efficacy is to have a placebo group size greater than 200 and to use (cognitive testing methods) at least four times and in English," researcher Dr. Lon S. Schneider, professor of psychiatry and neurology at the University of Southern California Keck School of Medicine, said in a news release issued from the conference.

The second study, which looked at trials of the drug donepezil during the 1990s, showed that the length of the placebo study may be of increasing importance. Placebo groups experienced slower declines in cognitive functions in trials done later in the decade, but this was mitigated when the trial period was longer.

"Our results indicate that patients with Alzheimer's entering the later clinical trials appear to be experiencing a slower rate of decline in memory and thinking processes," researcher Roy Jones, director of The Research Institute for the Care of Older People, in Bath, England, said in the same news release. "These observations are potentially important for the future design of clinical trials in people with Alzheimer's. For example, it may be necessary to conduct longer duration research studies -- more than 24 weeks -- to ensure any effects of treatment can be fully evaluated."

More information

The Alzheimer's Association has more about Alzheimer's disease.



-- Kevin McKeever



SOURCE: Alzheimer's Association, news release, July 28, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting
3. Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi
4. Researchers disprove long-standing belief about HIV treatment
5. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
6. Clinical Trial Concluded For New Wrinkle Treatment
7. Has cancer spread? Research identifies best way to find answers so treatment can begin
8. Minimally Invasive Treatment Improves Male Fertility
9. Minimally invasive treatment improves male fertility
10. Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
11. Promising results in deep brain stimulation for patients with treatment-resistant depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: